Culić Srdana, Armanda Visnja, Kuljis Dubravka, Kuzmic Ivana, Pranic-Kragic Ankica, Jankovic Stipan
Paediatrics Clinic, Clinical Hospital, Split, Croatia.
Pediatr Hematol Oncol. 2006 Dec;23(8):661-6. doi: 10.1080/08880010600957259.
Biologic treatments including antibody-based therapies are still in early-phase development in Hodgkin lymphoma. The authors present the case of a 10-year-old girl with massive, solid, unilateral cervical, nodular lymphocyte-predominant Hodgkin lymphoma. Chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]) and radiotherapy were given, according to the Italian Association of Pediatric Hematology and Oncology (AIEOP) MH-96 study protocol, but the patient failed to enter complete remission. Soon after, 6 intravenous infusions of the chimeric anti-CD20 monoclonal antibody rituximab 375 mg/m2 were administered, resulting in complete remission. The patients is still in continuous complete remission for 2 years. Novel therapies, such as rituximab, may be useful for children with CD20+ nodular lymphocyte-predominant Hodgkin lymphoma. To the authors' knowledge, this is the first report of CD20+ nodular lymphocyte-predominant Hodgkin lymphoma treated with rituximab in children. Further controlled trials and long-term outcome studies are warranted to define its clinical application and to improve the care of patients.
包括基于抗体的疗法在内的生物治疗在霍奇金淋巴瘤中仍处于早期开发阶段。作者报告了一例10岁女孩，患有巨大、实性、单侧颈部结节性淋巴细胞为主型霍奇金淋巴瘤。根据意大利儿科血液学和肿瘤学协会（AIEOP）的MH - 96研究方案，给予了化疗（多柔比星、博来霉素、长春花碱和达卡巴嗪[ABVD]）和放疗，但该患者未能实现完全缓解。此后不久，给予了6次静脉输注375 mg/m²的嵌合抗CD20单克隆抗体利妥昔单抗，结果实现了完全缓解。该患者持续完全缓解已达2年。新型疗法，如利妥昔单抗，可能对CD20阳性结节性淋巴细胞为主型霍奇金淋巴瘤患儿有用。据作者所知，这是儿童CD20阳性结节性淋巴细胞为主型霍奇金淋巴瘤采用利妥昔单抗治疗的首例报告。有必要进行进一步的对照试验和长期预后研究，以确定其临床应用并改善患者的治疗。
